genetic analysis of the leukemia cells was normal. At presentation she was noted to have bilateral papilloedema and developed a sixth nerve palsy due to benign intracranial Pancytopenia with severe bone marrow dysplasia following allogeneic bone marrow transplantation for hypertension, probably related to obesity and the combined oral contraceptive pill. She was commenced on acetazolaacute myeloid leukemia (M6) may pose a diagnostic problem. We report a case of M6 acute myeloid leukemide with subsequent resolution of her neurological symptoms. For her AML, she received two courses of combimia in which progressive macrocytosis, pancytopenia and severe bone marrow dysplasia induced by nation chemotherapy consisting of standard doses of mitozantrone and Ara-C, but failed to achieve a complete acetazolamide therapy developed after successful engraftment of a donor marrow. We discuss the diagremission. She therefore underwent an allogeneic BMT from her HLA-identical brother who also had osteogenesis nostic problems and the usefulness of conventional cytogenetics and interphase fluorescence in situ hybridisimperfecta. Conditioning therapy comprised busulphan (16 mg/kg) and cyclophosphamide (120 mg/kg), and she ation in excluding recipient myelodysplasia relapse. We also suggest that acetazolamide should be used with caureceived cyclosporin A for graft-versus-host disease (GVHD) prophylaxis. The peri-transplant period was tion, especially following bone marrow transplantation.
/l on day +42. Myelodysplasia is a well-recognised complication followDespite the initial satisfactory bone marrow engraftment, ing autologous bone marrow transplantation (BMT). 1 It normalisation of peripheral blood counts failed to occur. occurs as a result of previous damage to haemopoietic proShe developed progressive macrocytosis and pancytopenia, genitor cells by the chemo-radiotherapy used in the initial despite normal serum vitamin B12 and folate levels. Bone treatment of the primary malignant disease. Severe myelomarrow examination 2 and 4 months post-BMT showed dysplasia following allogeneic BMT is, however, extremely severely dysplastic features involving all three lineages, rare. It poses diagnostic difficulties, especially if the allofeatures similar to those when she first presented with AML geneic BMT had been carried out for M6 AML, a condition ( Figure 1 ). On this basis, it was suspected that either her in which dysplasia is a prominent feature. We report an disease had relapsed or that the donor marrow had evolved interesting case of severe pancytopenia with dysplastic into myelodysplasia de novo. However, repeated bone marcharacteristics in the bone marrow induced by acetazolarow cytogenetics and fluorescence in situ hybridisation mide following allogeneic BMT. We discuss the diagnostic using a sex-specific probe showed the presence of only nordifficulties and demonstrate the usefulness of diagnostic mal male (donor) cells. Donor peripheral blood counts and tools such as conventional cytogenetics and interphase bone marrow morphology examined at the same time were fluorescence in situ hybridisation in such a situation. also normal.
To exclude possible drug-induced myelodysplasia, her acetazolamide therapy was discontinued. Within 2 weeks Case report her peripheral cytopenia improved, and within 10 weeks bone marrow morphology reverted back to normal, indicat-A 16-year-old girl with a history of osteogenesis imperfecta ing that the acetazolamide was responsible for the dysplasia presented with pancytopenia, a severely dysplastic bone induced in the donor marrow. marrow, and was diagnosed with acute myeloid leukemia has not previously been associated with myelodysplasia. As exclude the possibility that the donor cells might have preferentially entered into mitosis, giving false negaa result, acetazolamide was not initially considered high on the list of differential diagnoses for this patient. Instead, tive results by metaphase G-banding, interphase fluorescence in situ hybridisation using a sex-specific probe was investigations to exclude primary disease relapse and the development of myelodysplasia de novo in the donor maralso used. This interesting case illustrates the diagnostic difficulties row were undertaken. Although the primary leukemia cells in this case showed no cytogenetic abnormality, we were which may arise when myelodysplasia occurs following allogeneic BMT for M6 AML and the importance of diagfortunate that there was a sex-mismatch in the allogeneic BMT, allowing the definitive determination of the origin of nostic tools such as conventional cytogenetics and fluorescence in situ hybridisation. It also suggests that acetazolathe dysplastic post-transplant marrow cells by sex chromosome analysis. This was first carried out by conventional mide can induce severe pancytopenia with dysplastic characteristics in the bone marrow and should be used with metaphase cytogenetics which showed that all the metaphases were donor cells. To confirm this further and to caution, especially following BMT.
